
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has seen a significant appreciation of nearly 90% in its stock value over the past month, indicating strong market sentiment. The company’s advanced multi-cancer early detection blood test, underpinned by favorable results from the PATHFINDER 2 study and positive insights from key opinion leaders, suggests a promising outlook for gaining regulatory approval and accessing a substantial total addressable market estimated at approximately $3.7 billion in the UK by 2026. Additionally, GRAIL’s strategic partnerships and anticipated influx of over $400 million to its balance sheet enhance its financial outlook and position in the burgeoning early cancer detection market.
Bears say
GRAIL Inc has reported continuous significant net losses since its inception, with projections indicating that it will maintain this trend due to ongoing studies, regulatory approval efforts, and the necessity to expand its operational infrastructure. The company faces multiple risks, including potential delays in reimbursement pathways, adoption challenges for its innovative multi-cancer early detection test, and competitive threats from established diagnostics firms with more resources. Additionally, the expectation of rising Selling, General and Administrative (SG&A) expenses, coupled with possible financing shortfalls and setbacks in clinical study timelines, creates substantial concerns regarding GRAIL's ability to effectively commercialize its products.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares